Valsartan Tablets 40 mg USP recalled over manufacturing violations
- Recall date
- March 7, 2019
- Source
- U.S. Food & Drug Administration (FDA) — enforcement report
- Official notice title
- Rising Pharmaceuticals, Inc. recalls Valsartan Tablets 40 mg USP, 30 tablet bottles, Rx, Only, Distributed by: Acetris Health, LLC, Saddle Brook, NJ, Manufa…
- Recall number
- D-1052-2019
- FDA classification
- Class II
- Brand / firm
- Rising Pharmaceuticals, Inc.
- Sold / distributed
- Product was distributed to 6 major distributors who may have further distributed the product throughout the United States.
Why it was recalled
CGMP Deviations; Detection of a trace amount of unexpected impurity N- nitrosodiethylamine (NDEA) found in finished products
Class II means using this product may cause temporary or medically reversible health problems; the chance of serious harm is remote.
What was recalled
Valsartan Tablets 40 mg USP, 30 tablet bottles, Rx, Only, Distributed by: Acetris Health, LLC, Saddle Brook, NJ, Manufactured by: Aurolife Pharma LLC, Dayton, NJ ---- NDC 52343-122-30
Get recall alerts
Free email alert whenever Rising Pharmaceuticals, Inc. has a new recall — straight from official government data. Unsubscribe anytime.
More recalls from: Rising Pharmaceuticals, Inc.